Tag : Monoclonal Antibody

Latest News

Monoclonal antibody HB27 shows potent neutralizing activity against SARS-CoV-2

Newsemia
A new study reports a very promising anti-SARS-CoV-2 monoclonal antibody, HB27, that appears to have two distinct mechanisms of action inhibiting the virus-host cell interaction...
Latest News

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

Newsemia
In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the...
Latest News

Bispecific sybodies show potential against SARS-CoV-2

Newsemia
As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November...
Latest News

NIH launches new study to streamline COVID-19 treatments for larger clinical studies

Newsemia
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain...
Neurology

CGRPs Promising for Prevention of Chronic Cluster Headache

Newsemia
Treatment with CGRP monoclonal antibodies may reduce the frequency of chronic cluster headache attacks in patients with an inadequate response to other preventive medications, new...
Latest News

Targeted treatment for systemic lupus erythematosus

Newsemia
A team of researchers from Charité – Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune...
Neurology

B Cell Test Predicts Alemtuzumab Autoimmunity in MS

Newsemia
Analyzing B cell counts before treatment could help select patients for the drug, a new study suggests. Medscape Medical News Source link...
Neurology

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

Newsemia
Medscape Medical News Source link...
Neurology

Lowering Rituximab Dose in Patients With MS Safe, Effective

Newsemia
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and...
Latest News

UChicago Medicine launches clinical trial to test the potential of antibody against SARS-CoV-2

Newsemia
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19,...
Neurology

Negative Phase 2 Trial Data Ends Development of PSP Drug

Newsemia
Phase 2 trial results show gosuranemab did not meet primary or key secondary endpoints in patients with progressive supranuclear palsy, leading to discontinuation of the...
Neurology

PREVENT: Eculizumab May Lower Relapse Risk in NMOSD

Newsemia
Use of eculizumab resulted in significantly greater relapse reduction over placebo in patients with neuromyelitis optica spectrum disorder (NMSOD), new findings from the phase 3...
Neurology

Anti-CGRP Monoclonal Antibodies for Migraine Prevention

Newsemia
Dr Deborah Friedman reviews the new anti-CGRP monoclonal antibodies for migraine prevention. American Headache Society and Medscape Source link...
Neurology

Novel Anti-B-Cell Therapy Looks Promising in MS

Newsemia
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study....
Latest News

Antibody Screening Tools; Improving Workflows

Newsemia
Antibody screening tools have exponentially increased the rate that candidates can be screened, multiplexing will increase processing to thousands per hour.¬ Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy